The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Presentation
SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: results from a phase 2 study
Lin Wu, Haipeng Xu, Yulan Sun, Fangling Ning, Siyuan Huang, Dingzhi Huang, Yan Yu, Feng Ye, Dongqing Lv, Zhidong Pei, Junguo Lu, Tao Xu, Xingxiang Pu, Xiang Li, Ruoyu Wang, Laiyu Liu, Junfang Tang, Anwen Liu, Jing Lou, Weifeng Song
PD-1 x VEGF Bispecific Antibody | November 7, 2025 | SITC 2025
NCT06412471
Poster
SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: results from a phase 2 study
Lin Wu, Haipeng Xu, Yulan Sun, et al
PD-1 x VEGF Bispecific Antibody | November 5, 2025 | SITC 2025 2025
NCT06412471
Poster
A Phase II Trial to Evaluate the Safety and Efficacy of SSGJ -707, a Bispecific Antibody Targeting PD-1 and VEGF, in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer
Tianshu Liu, Xiaojing Xu, Wei Li, Yanqiao Zhang, Xiaobo Du, Zuoxing Niu, Hong Qiu, Zengqing Guo, Yanhong Deng, Mingquan Cai, Jing Lv, Lingxing Feng, Hong Zong, Mulin Liu, Xiaojun Xiang, Yulong Zheng, Yarong Guo, Tao Wu, Jing Lou, Weifeng Song
PD-1 x VEGF Bispecific Antibody | October 17, 2025 | ESMO 2025
NCT06493760
Poster
A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC
Lin Wu, Jun Yao, Yulan Sun, Ruoyu Wang, Xiang Li, Bolin Chen, Qian Chu, Qing Bu, Yong Fang, Jun Zhao, Weizhen Huang, Jin Zhou, Qiming Wang, Jie Li, Yongzhong Luo, Yan Yu, Tienan Yi, Jing Lou, Weifeng Song